Pemetrexed Pfizer 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0033/G 
This was an application for a group of variations. 
29/08/2022 
SmPC, Annex 
C.I.2.a - To update Sections 4.4 and 4.6 of the SmPC 
A.5.a - Administrative change - Change in the name 
and PL 
“Report from the CMD(h) meeting held on 20-21 July 2021” 
II, Labelling 
based on the recommended wording provided in the 
and/or address of a manufacturer/importer 
responsible for batch release 
A.2.a - Administrative change - Change in the 
concerning duration of contraception following the end of 
treatment with a genotoxic drug. The PL has been updated 
accordingly. 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
(invented) name of the medicinal product for CAPs 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0030/G 
This was an application for a group of variations. 
01/07/2022 
n/a 
B.III.z - Quality Change - CEP/TSE/Monographs - 
Other variation 
B.I.a.4.b - Change to in-process tests or limits 
applied during the manufacture of the AS - Addition 
of a new in-process test and limits 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.III.2.z - Change to comply with Ph. Eur. or with a 
Page 2/8 
 
 
 
 
 
 
 
 
 
national pharmacopoeia of a Member State - Other 
variation 
IB/0032 
B.II.f.1.e - Stability of FP - Change to an approved 
13/06/2022 
n/a 
stability protocol 
IB/0031/G 
This was an application for a group of variations. 
12/05/2022 
n/a 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.III.2.a.1 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - AS 
N/0029 
Minor change in labelling or package leaflet not 
03/03/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0028 
Minor change in labelling or package leaflet not 
14/09/2021 
31/01/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0027 
B.II.b.3.a - Change in the manufacturing process of 
08/04/2021 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IAIN/0026/G 
This was an application for a group of variations. 
08/02/2021 
31/01/2022 
Annex II and 
PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
Page 3/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
A.7 - Administrative change - Deletion of 
manufacturing sites 
X/0021 
Annex I_2.(c) Change or addition of a new 
23/07/2020 
30/09/2020 
SmPC, 
strength/potency 
Annex I_2.(d) Change or addition of a new 
pharmaceutical form 
Labelling and 
PL 
IB/0025 
C.I.11.a - Introduction of, or change(s) to, the 
24/09/2020 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
wording agreed by the competent authority 
II/0024 
B.II.b.4.d - Change in the batch size (including batch 
24/09/2020 
n/a 
size ranges) of the finished product - The change 
relates to all other pharmaceutical forms 
manufactured by complex manufacturing processes 
R/0022 
Renewal of the marketing authorisation. 
25/06/2020 
10/08/2020 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Pemetrexed Hospira in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
Page 4/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0023/G 
This was an application for a group of variations. 
24/06/2020 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
II/0020/G 
This was an application for a group of variations. 
16/01/2020 
12/05/2020 
Annex II and 
PL 
B.I.a.1.b - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Introduction of a manufacturer of the AS supported 
by an ASMF 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0019 
C.I.2.a - Change in the SPC, Labelling or PL of a 
28/05/2019 
12/05/2020 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
N/0018 
Minor change in labelling or package leaflet not 
12/04/2019 
12/05/2020 
PL 
Page 5/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
connected with the SPC (Art. 61.3 Notification) 
IA/0017 
A.7 - Administrative change - Deletion of 
18/03/2019 
n/a 
manufacturing sites 
IA/0016 
A.7 - Administrative change - Deletion of 
19/12/2018 
n/a 
manufacturing sites 
N/0015 
Minor change in labelling or package leaflet not 
31/10/2018 
12/05/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
T/0014 
Transfer of Marketing Authorisation 
06/08/2018 
18/10/2018 
SmPC, 
Labelling and 
PL 
IAIN/0013 
C.I.z - Changes (Safety/Efficacy) of Human and 
24/04/2018 
18/10/2018 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IA/0012 
A.5.b - Administrative change - Change in the name 
28/02/2018 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
N/0011 
Minor change in labelling or package leaflet not 
20/11/2017 
08/05/2018 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0010 
B.II.d.1.a - Change in the specification parameters 
15/09/2017 
n/a 
and/or limits of the finished product - Tightening of 
specification limits 
IB/0009 
C.I.2.a - Change in the SPC, Labelling or PL of a 
11/05/2017 
08/05/2018 
SmPC, 
generic/hybrid/biosimilar products following 
Labelling and 
Page 6/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
PL 
N/0008 
Minor change in labelling or package leaflet not 
16/02/2017 
08/05/2018 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IA/0007 
A.7 - Administrative change - Deletion of 
03/02/2017 
n/a 
manufacturing sites 
IB/0006 
C.I.11.z - Introduction of, or change(s) to, the 
14/01/2017 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IAIN/0005 
C.I.11.a - Introduction of, or change(s) to, the 
08/07/2016 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
wording agreed by the competent authority 
N/0004 
Update of the package leaflet with revised contact 
17/06/2016 
08/05/2018 
PL 
details of the local representatives for Belgium, 
Germany, Spain, Ireland, Luxembourg, the 
Netherlands, Austria and Portugal. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
IG/0693 
B.II.b.1.a - Replacement or addition of a 
02/06/2016 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
Page 7/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0002 
B.II.d.2.a - Change in test procedure for the finished 
25/02/2016 
n/a 
product - Minor changes to an approved test 
procedure 
IG/0645 
C.I.8.a - Introduction of or changes to a summary of 
17/12/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
Page 8/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
